Boston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?

Simply Wall St.07-17

Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2652843352?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234","is_english":true,"pubTime":"2026-07-17 22:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2652843352","market":"us","top_or_hot":-1,"title":"Boston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?","media":"Simply Wall St.","content":"<div>\n<p>Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Boston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBoston Scientific (BSX) Recalls Endoscopy Devices, Is The Stock A Bargain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-07-17 22:25 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2357305700.SGD","symbol_name":"Allianz Global Artificial Intelligence ET H2-SGD","start_time":0,"source_url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock","article_id":"2652843352","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/company-cover/317627-main-header/1756255518234"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/healthcare/nyse-bsx/boston-scientific/news/boston-scientific-bsx-recalls-endoscopy-devices-is-the-stock","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2652843352","pubTimestamp":1784298331,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting tens of thousands of units globally.\nSee our latest analysis for Boston Scientific.\nThe recalls arrive after a period of sharp share price weakness, with Boston Scientific’s stock down 30.53% on a 3 month share price return basis and 52.89% year to date. The 1 year total shareholder return has...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2357305700.SGD":"Allianz Global Artificial Intelligence ET H2-SGD","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU0432979614.USD":"JPM GLOBAL HEALTHCARE \"A\" ACC","IE0002141913.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I2\" (USD) ACC","LU2112291526.USD":"BGF WORLD HEALTHSCIENCE \"A4\" (USD) INC","LU2362540622.SGD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (SGDHDG) ACC","LU1548497426.USD":"安联环球人工智能AT Acc","LU1804176565.USD":"EASTSPRING INV GLOBAL GROWTH EQUITY \"A\" (USD) ACC","LU1718418525.SGD":"JPMorgan Investment Funds - Global Select Equity A (acc) SGD","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","LU2491050154.USD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (USD) ACC","LU2242649171.HKD":"FIDELITY FUNDS GLOBAL THEMATIC OPPORTUNITIES \"A\" (HKD) ACC","LU1791710400.SGD":"Fidelity Global Demographics A-ACC-SGD","LU0011850046.USD":"贝莱德全球长线股票 A2 USD","LU1061106388.HKD":"BGF WORLD HEALTHSCIENCE \"A2\" (HKDHDG) ACC","IE00BFTCPJ56.SGD":"Janus Henderson Global Life Sciences A Acc SGD","BK4581":"高盛持仓","BSX":"波士顿科学","LU0048584097.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) INC","LU2265009873.SGD":"Eastspring Investments - Global Growth Equity AS SGD-H","LU0345769128.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","LU0823416689.USD":"BNP PARIBAS HEALTH CARE INNOVATORS \"C\" (USD) ACC","LU0225283273.USD":"SCHRODER ISF GLOBAL EQUITY ALPHA \"A\" (USD) ACC","LU0122379950.USD":"贝莱德世界健康科学A2","SGXZ57979304.SGD":"United Global Healthcare A Acc SGD-H","LU1989771016.USD":"东方汇理环球老龄化投资基金 A2 Acc","LU0187121727.USD":"FIDELITY SUSTAINABLE US EQUITY \"A\" (USD) INC","LU0251132253.USD":"FIDELITY FUNDS  GLOBAL THEMATIC OPPORTUNITIES \"A\" (USD) ACC","LU2506952170.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) INC","LU2506951875.HKD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (HKDHDG) ACC","BSX.AU":"BLACKSTONE MINERALS LTD","LU2324357040.USD":"HSBC GIF GLOBAL EQUITY SUSTAINABLE HEALTHCARE \"AC\" (USD) ACC","LU2506952097.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"CRH\" (USDHDG) ACC","IE0009355771.USD":"骏利亨德森环球生命科技A Acc","LU1989772840.SGD":"CPR Invest - Climate Action A2 Acc SGD-H","LU0266013472.USD":"AXA WF - Framlington Longevity Economy A Cap USD","LU1989772923.USD":"CPR Invest - Climate Action A2 Acc USD-H","LU1057294990.SGD":"Blackrock World Healthscience A2 SGD-H","LU1153585028.USD":"BGF GLOBAL LONG-HORIZON EQUITY  \"A4\" (USD) INC","LU2362541513.USD":"WELLINGTON NEXT GENERATION GLOBAL EQUITY \"A\" (USD) ACC","LU0353189680.USD":"富国美国全盘成长基金Cl A Acc","IE00B2B36J28.USD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"I1\" (USD) INC","LU2087625088.SGD":"ALLSPRING  US ALL CAP GROWTH \"A\" (SGDHDG) ACC","LU0950375773.USD":"BNP PARIBAS SUSTAINABLE GLOBAL LOW VOL EQUITY \"C\" (USD) INC A","BK4588":"碎股","IE00BJT1NW94.SGD":"JANUS HENDERSON GLOBAL LIFE SCIENCES \"A2\" (SGDHDG) ACC","LU1720051017.SGD":"Allianz Global Artificial Intelligence AT Acc H2-SGD","LU1989764748.USD":"东方汇理环球颠覆性机遇A2 Acc"},"translate_title":"波士顿科学公司 (BSX) 召回内窥镜设备，该股便宜吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BSX":1.5,"BSX.AU":1.5},"content_text":"Boston Scientific (BSX) is under scrutiny after a series of voluntary Class II recalls of its CRE and CRE Pro Wireguided endoscopy devices, prompted by potential sterile packaging breaches affecting tens of thousands of units globally. See our latest analysis for Boston Scientific. The recalls arrive after a period of sharp share price weakness, with Boston Scientific’s stock down 30.53% on a 3 month share price return basis and 52.89% year to date. The 1 year total shareholder return has declined 57.36%, suggesting momentum has been fading despite earlier growth in the underlying business. If this kind of event driven move has you reassessing your watchlist, it can be useful to look across other healthcare technology opportunities using the 39 healthcare AI stocks After a 52.89% year to date share price decline, the question with Boston Scientific is simple but important: has most of the repricing already happened, or is the bulk of any potential upside still ahead from here? AdvertisementMost Popular Narrative: 54.9% Undervalued According to the most followed Boston Scientific narrative, the latest close at $44.62 sits well below an assessed fair value of $98.90, putting a spotlight on how the recent sell off compares to long term potential.  The immediate impact of the Penumbra acquisition has been somewhat heavy on the stock’s valuation for a few key reasons: *   Earnings Dilution: The acquisition is expected to be dilutive to adjusted earnings per share (EPS) by approximately $0.06 to $0.08 in the first full year. Investors often react to this \"EPS drag\" by pulling back, which we have seen in the recent price dips.  Read the complete narrative. Want to see why this narrative still assigns a much higher fair value to Boston Scientific? The core assumptions rest on future earnings power, richer margin potential and how those feed into long run cash flows. The full narrative spells out the revenue trajectory, profitability profile and discount rate that have to hold for $98.90 to make sense. Result: Fair Value of $98.90 (UNDERVALUED) Have a read of the narrative in full and understand what's behind the forecasts. However, Boston Scientific still faces key risks, including the successful integration of Penumbra and the management of higher debt levels, which could weigh on flexibility if conditions tighten. Find out about the key risks to this Boston Scientific narrative. Next Steps With sentiment on Boston Scientific clearly mixed, this is a moment to move fast, review the numbers firsthand and decide where you stand by weighing the 4 key rewards. Looking for more investment ideas beyond Boston Scientific? If Boston Scientific has you rethinking where to focus next, it is worth scanning a few different angles so you do not miss other compelling setups. Use the Simply Wall St Screener to quickly compare fresh ideas, narrow your watchlist, and pressure test whether Boston Scientific still deserves a spot alongside new candidates.  Target potential mispriced opportunities by checking companies highlighted in the 49 high quality undervalued stocks that pair solid fundamentals with a gap between price and assessed worth. Strengthen the quality of your portfolio by focusing on companies in the solid balance sheet and fundamentals stocks screener (47 results) that prioritize financial resilience and cleaner balance sheets. Get ahead of the crowd by reviewing companies surfaced in the screener containing 20 high quality undiscovered gems that combine strong fundamentals with relatively low market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if Boston Scientific might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"-1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2652843352","isCrawlerRequest":true}